Qingwei Meng

Qingwei Meng

Auto-generated profile, based on publicly available information

Qingwei Meng

Department of Medical Oncology, Harbin Medical University Cancer Hospital, Haping Road 150 of Nangang District, Harbin, Heilongjiang Province 150081, PR China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Molecular Immunology
Verified
Journal Article
Closed access
DCDehai Che
Dehai Che
SZShuai Zhang
Shuai Zhang
ZJZihan Jing
Zihan Jing
LSLihua Shang
Lihua Shang
SJShi Jin
Shi Jin
YYYan Yu
Yan Yu

25 April 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TWTing Wang
Ting Wang
YXYing Xing
Ying Xing
QMQingwei Meng
Qingwei Meng
HLHailing Lu
Hailing Lu
WLWei Liu
Wei Liu
LCLi Cai
Li Cai
Non-small cell lung cancer (NSCLC) is a devastating disease with a heterogeneous prognosis, and the molecular mechanisms underlying tumor progression remain elusive. Mammalian Eps15 homology domain 1 (EHD1) plays a promotive role in tumor progression, but its role in cancer angiogenesis remains unknown. This study thus explored the role of EHD1 in angiogenesis in NSCLC. The changes in angiogenesis were evaluated through human umbilical vein endothelial cell (HUVEC) proliferation, migration and tube formation assays. The impact of EHD1 on β2-adrenoceptor (β2AR) signaling was evaluated by Western blotting, quantitative real-time polymerase chain reaction (qRT-PCR) analysis, and enzyme-linked immunosorbent assay (ELISA). The interaction between EHD1 and β2AR was confirmed by immunofluorescence (IF) and coimmunoprecipitation (Co-IP) experiments, and confocal microscopy immunofluorescence studies revealed that β2AR colocalized with the recycling endosome marker Rab11, which indicated β2AR endocytosis. Xenograft tumor models were used to investigate the role of EHD1 in NSCLC tumor growth. The microarray analysis revealed that EHD1 was significantly correlated with tumor angiogenesis, and loss- and gain-of-function experiments demonstrated that EHD1 potentiates HUVEC proliferation, migration and tube formation. EHD1 knockdown inhibited β2AR signaling activity, and EHD1 upregulation promoted vascular endothelial growth factor A (VEGFA) and β2AR expression. Interestingly, EHD1 interacted with β2AR and played a novel and critical role in β2AR endocytic recycling to prevent receptor degradation. Aberrant VEGFA or β2AR expression significantly affected EHD1-mediated tumor angiogenesis. The proangiogenic role of EHD1 was confirmed in xenograft tumor models, and immunohistochemistry (IHC) analysis confirmed that EHD1 expression was positively correlated with VEGFA expression, microvessel density (MVD) and β2AR expression in patient specimens. Collectively, the data obtained in this study suggest that EHD1 plays a critical role in NSCLC angiogenesis via β2AR signaling and highlight a potential target for antiangiogenic therapy.

17 March 2014 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XCXuesong Chen
Xuesong Chen
LSLichun Sun
Lichun Sun
YCYingying Cong
Yingying Cong
TZTingting Zhang
Tingting Zhang
QLQiushi Lin
Qiushi Lin
XDXiaoqun Dong
Xiaoqun Dong
Bone scanning (BS), liver ultrasonography (LUS), and chest radiography (CXR) are commonly recommended for baseline staging in patients with newly diagnosed breast cancer. The purpose of this study is to demonstrate whether these tests are indicated for specific patient subpopulation based on clinical staging and molecular subtype.

10 December 2020 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
JGJunqing Gan
Junqing Gan
QMQingwei Meng
Qingwei Meng
YLyanjing li
yanjing li
Background: Lung cancer remains a common malignancy and the leading cause of cancer-related deaths in the world. Although dramatic progress made in multimodal therapies, it still has a poor prognosis. The Family with sequence similarity 83 (FAM83) of poorly characterized proteins are defined by the presence of the conserved DUF1669 domain of unknown function at their N-termini, most of which significantly elevated levels of expression in multiple cancers. However, the expression and prognostic values of different FAM83 family in lung cancer, especially in non-small-cell lung cancer (NSCLC), have not been clarified.Methods: ONCOMINE, UALCAN, GEPIA, Kaplan–Meier Plotter, cBioPortal, and STRING databases were utilized in this study.Results: The transcriptional levels of FAM83A/B/C/D/F/G/H were up-regulated in patients with NSCLC. A noticeable correlation was found between the over-expressions of FAM83A/B/D/F/H and clinical cancer stages in NSCLC patients. Besides, higher mRNA expressions of FAM83A/B/C/D/F/H were discovered to be expressively associated with overall survival (OS) in lung cancer patients, furthermore, FAM83A, FAM83C, and FAM83H in OS group achieved 0.9475/1, 0.971897/1, and 0.9454545/0.8974359 specificity/sensitivity in distinguishing short survivors from long survivors, respectively. Moreover, a high mutation rate of FAM83 family (51%) was also observed in lung adenocarcinoma (LUAD) patients, and genetic alteration in the FAM83 family was associated with shorter OS and disease-free survival (DFS) in LUAD patients.Conclusion: Our results indicated that FAM83A/H might play important roles in NSCLC tumorigenesis and might be risk factor for the survival of NSCLC patients.

3 April 2013 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
HLHailing Lu
Hailing Lu
QMQingwei Meng
Qingwei Meng
YWYuan Wen
Yuan Wen
JHJing Hu
Jing Hu
YZYanbin Zhao
Yanbin Zhao
LCLi Cai
Li Cai
Background One of the main challenges of lung cancer research is identifying patients at high risk for recurrence after surgical resection. We evaluated the prognostic power of four proteins in the endocytic pathway in 114 non-small cell lung cancer patients (NSCLC). Methods We tested the four proteins (epidermal growth factor receptor [EGFR], RAB11FIP3, EHD1, and caveolin-1), critical nodes in the endocytosis/recycling pathway, by immunohistochemistry in paraffin sections from 114 non-small cell lung cancer patients. We analyzed the correlation between our target proteins and clinical variables. Within these variables, an overall survival (OS) prediction model was constructed using Cox proportional hazard regression. Results EHD1 expression correlated with gender (P = 0.001), histology type (P < 0.001), and EGFR expression (P = 0.008), but not with any of the other clinical parameters. Statistical correlation analysis showed that the expression of EHD1 positively correlated with high level of EGFR (P < 0.001) and RAB11FIP3 (P < 0.001), and the expression of caveolin-1 positively correlated with high level of EGFR (P < 0.001) in the NSCLC samples. EHD1 expression was an OS prognostic factor for all of the patients (P = 0.009), for the group of adjuvant chemotherapy-treated patients (P = 0.006), and for the EGFR positive patients (P = 0.034). Conclusions We identified EHD1 as a strong prognostic predictive factor in NSCLC. The expression level of EHD1 would potentially be useful in developing customized strategies for managing lung cancer, such as the selection of patients eligible for chemotherapy.

1 October 2020 in Molecular Immunology
Verified
Journal Article
Closed access
DCDehai Che
Dehai Che
SZShuai Zhang
Shuai Zhang
ZJZihan Jing
Zihan Jing
LSLihua Shang
Lihua Shang
SJShi Jin
Shi Jin
YYYan Yu
Yan Yu